MANKIND PHARMA, WATCH OUT FOR BREAKOUTmankind pharma look for breakout, from last two days price is moving up and the volumes are rising.
education purpose only.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
50.90 INR
19.13 B INR
103.34 B INR
104.43 M
About MANKIND PHARMA LTD
Sector
Industry
CEO
Sheetal Arora
Website
Headquarters
New Delhi
Founded
1986
ISIN
INE634S01028
FIGI
BBG01G9WXG92
Mankind Pharma Ltd. engages in the development, manufacture, and marketing of pharmaceutical formulations across acute and chronic therapeutic areas. It offers products under the brands of Nurokind, Telmikind, Manforce, Unwanted, Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Prega News, Dydroboon, Cefakind, Monticope, and Caldikind. The company was founded by Ramesh Chand Juneja in 1986 and is headquartered in New Delhi, India.
ATH breakoutGood volume buildup in daily time frame.
ATH breakout and retest successfully.
Fundamental's are good.
FII stakes are up.
NOTE: I do my analysis, do yours before trade.
Eat🍜 Sleep😴 TradingView📈 Repeat 🔁
MANKIND PHARMA LTD S/R Support and Resistance Levels:
Support Levels: These are price points (green line/shade) where a downward trend may be halted due to a concentration of buying interest. Imagine them as a safety net where buyers step in, preventing further decline.
Resistance Levels: Conversely, resistance levels (re
MANKIND PHARMA- MULTIPLE SUPPORTS & RESISTANCESI have drawn support and resistance lines. it may be following the trend lines. May not be as well... need more time to see if the trend lines are being supported by the stock. As of now, volumes are missing and stock has held its price. Earnings on 28th August. Stock likely to remain range bound. M
MANKIND PHARMABullish Wedge Pattern is forming.
Wait for Retest.
Than Make Your Position.
Idea shared Only for Educational Purpose.
W PATTERN HAS FORMED1 DAY Time Frame- W PATTERN HAS FORMED.
Just keep patience to get supported on 61.80%.
3 times rejection from fib based extention 78.60% and got supported from 50.00% it's time to make new entries.
IDEA SHARED ONLY FOR EDUCATIONAL PURPOSE.
MANKIND PHARMA making breakout from 3-month consolidation rangeMANKIND PAHRMA is making breakout from a 3-month consolidation range. Its relative performance to CNX 500 turned positive, & the momentum indicator, RSI has not gone below its bull support zone of 60 during the entire consolidation period & that indicats strength in its bullish momentum. The structu
3rd of the 3rd is coming in MANKINDIn the weekly timeframe, it is evident that mankind has successfully navigated through its first and second wave, and is now poised for the commencement of its third wave. Transitioning to the daily chart, we observe the initiation of this anticipated third wave, with the completion of its first sub
mankind pharma 4hr time frame buy@ 1819 target @ 1873, 1893, mankind pharma 4hr time frame
buy@ 1819 target @ 1873, 1893, 1899, 1929.70
channel breakout
risk reward 1:2
its just a view trade @ your own risk
sl@ 1766
See all ideas
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
797MPL27
MPL-7.97%-16-11-27-PVTYield to maturity
—
Maturity date
Nov 16, 2027
799MPL26A
MPL-7.99%-16-10-26-PVTYield to maturity
—
Maturity date
Oct 16, 2026
799MPL26
MPL-7.99%-16-4-26-PVTYield to maturity
—
Maturity date
Apr 16, 2026
See all MANKIND bonds
Related stocks
Frequently Asked Questions
The current price of MANKIND is 2,427.90 INR — it has increased by 3.26% in the past 24 hours. Watch MANKIND PHARMA LIMITED stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on BSE exchange MANKIND PHARMA LIMITED stocks are traded under the ticker MANKIND.
MANKIND stock has risen by 0.66% compared to the previous week, the month change is a 10.41% rise, over the last year MANKIND PHARMA LIMITED has showed a 7.90% increase.
We've gathered analysts' opinions on MANKIND PHARMA LIMITED future price: according to them, MANKIND price has a max estimate of 3,300.00 INR and a min estimate of 2,150.00 INR. Watch MANKIND chart and read a more detailed MANKIND PHARMA LIMITED stock forecast: see what analysts think of MANKIND PHARMA LIMITED and suggest that you do with its stocks.
MANKIND reached its all-time high on Dec 23, 2024 with the price of 3,050.00 INR, and its all-time low was 1,240.75 INR and was reached on May 22, 2023. View more price dynamics on MANKIND chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MANKIND stock is 4.37% volatile and has beta coefficient of 0.41. Track MANKIND PHARMA LIMITED stock price on the chart and check out the list of the most volatile stocks — is MANKIND PHARMA LIMITED there?
Today MANKIND PHARMA LIMITED has the market capitalization of 970.10 B, it has decreased by −3.19% over the last week.
Yes, you can track MANKIND PHARMA LIMITED financials in yearly and quarterly reports right on TradingView.
MANKIND PHARMA LIMITED is going to release the next earnings report on May 14, 2025. Keep track of upcoming events with our Earnings Calendar.
MANKIND earnings for the last quarter are 9.55 INR per share, whereas the estimation was 11.36 INR resulting in a −15.95% surprise. The estimated earnings for the next quarter are 10.03 INR per share. See more details about MANKIND PHARMA LIMITED earnings.
MANKIND PHARMA LIMITED revenue for the last quarter amounts to 32.30 B INR, despite the estimated figure of 32.06 B INR. In the next quarter, revenue is expected to reach 31.29 B INR.
MANKIND net income for the last quarter is 3.80 B INR, while the quarter before that showed 6.53 B INR of net income which accounts for −41.81% change. Track more MANKIND PHARMA LIMITED financial stats to get the full picture.
No, MANKIND doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Apr 15, 2025, the company has 19.54 K employees. See our rating of the largest employees — is MANKIND PHARMA LIMITED on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MANKIND PHARMA LIMITED EBITDA is 29.53 B INR, and current EBITDA margin is 24.98%. See more stats in MANKIND PHARMA LIMITED financial statements.
Like other stocks, MANKIND shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MANKIND PHARMA LIMITED stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MANKIND PHARMA LIMITED technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MANKIND PHARMA LIMITED stock shows the buy signal. See more of MANKIND PHARMA LIMITED technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.